Are multiple sclerosis patients risk-takers?

QJM: An International Journal of Medicine

Volumn 98, Issue 12, 2005, Pages 895-911

  Hawkes, C H ^a  

^a OLDCHURCH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA INTERFERON; CANNABIS; CAROTENOID; ESTROGEN; GLATIRAMER; HEPATITIS B VACCINE; INFLUENZA VACCINE; ORAL CONTRACEPTIVE AGENT; RECREATIONAL DRUG; TETANUS TOXOID; VITAMIN D;

ALCOHOL CONSUMPTION; CHOLESTEROL INTAKE; DRUG ABUSE; DRUG SAFETY; EPSTEIN BARR VIRUS; HUMAN; INCIDENCE; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; ORAL CONTRACEPTION; PATHOGENESIS; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; SOCIAL ASPECT; ULTRAVIOLET RADIATION; VASCULAR DISEASE; VIRUS INFECTION; VITAMIN SUPPLEMENTATION;

EID: 30444440891     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hci135     Document Type: Review

References (102)

1. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB, et al. Parkinson's disease in twins. Adv Neurol 1984; 40:341-4.
2. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002; 52:276-84.
3. Tanner CM, Goldman SM, Aston DA, Ottman R, Ellenberg J, Mayeux R, et al. Smoking and Parkinson's disease in twins. Neurology 2002; 58:581-8.
4. Hernan MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, Ascherio A. Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Ann Neurol 2001; 50:780-6.
5. Antonovsky A, Leibowitz U, Smith HA, Medalie JM, Balogh M, Kats R, et al. Epidemiologic study of multiple sclerosis in Israel. I. An overall review of methods and findings. Arch Neurol 1965; 13:183-93.
6. Villard-Mackintosh L, Vessey MP. Oral contraceptives and reproductive factors in multiple sclerosis incidence. Contraception 1993; 47:161-8.
7. Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynaecol 1998; 105:1296-9.
8. Ghadirian P, Dadgostar B, Azani R, Maisonneuve P. A case-control study of the association between socio-demographic, lifestyle and medical history factors and multiple sclerosis. Can J Public Health 2001; 92:281-5.
9. Hernan MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 2001; 154:69-74.
10. Zorzon M, Zivadinov R, Nasuelli D, Dolfini P, Bosco A, Bratina A, et al. Risk factors of multiple sclerosis: A case-control study. Neurol Sci 2003; 24:242-7.
11. Riise T, Nortvedt MW, Ascherio A. Smoking is a risk factor for multiple sclerosis. Neurology 2003; 61:1122-4.
12. Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H. Cigarette smoking and the progression of multiple sclerosis. Brain 2005; 128:1461-5.
13. Hawkes CH. Smoking is a risk factor for subsequent multiple sclerosis: A meta-analysis. Mult Scler 2005; 11(Suppl. 1):125.
14. Clayton D, Hills M. Statistical Models in Epidemiology. Oxford, OUP, 1993:161
15. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology 2002; 59:674-8.
16. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19.
17. Quesnel S, Feinstein A. Multiple sclerosis and alcohol: A study of problem drinking. Mult Scler 2004; 10:197-201.
18. Patten SB, Metz LM, Reimer MA. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler 2000; 6:115-20.
19. Goodin DS. Survey of multiple sclerosis in northern California. Northern California MS Study Group. Mult Scler 1999; 5:78-88.
20. Bombardier CH, Blake KD, Ehde DM, Gibbons LE, Moore D, Kraft GH. Alcohol and drug abuse among persons with multiple sclerosis. Mult Scler 2004; 10:35-40.
21. Brosseau L, Philippe P, Methot G, Duquette P, Haraoui B. Drug abuse as a risk factor of multiple sclerosis: Case-control analysis and a study of heterogeneity. Neuroepidemiology 1993; 12:6-14.
22. Lindegard B. Diseases associated with multiple sclerosis and epilepsy. A population cohort study of 159,200 middle-aged, urban, native Swedes observed over 10 years (1970-79). Acta Neurol Scand 1985; 71:267-77.
23. Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R. Nutritional factors in the aetiology of multiple sclerosis: A case-control study in Montreal, Canada. Int J Epidemiol 1998; 27:845-52.
24. Warren SA, Warren KG, Greenhill S, Paterson M. How multiple sclerosis is related to animal illness, stress and diabetes. Can Med Assoc J 1982; 126:377-82, 385.
25. Kannel WB. Oral contraceptive hypertension and thromboembolism. Int J Gynaecol Obstet 1978; 16:466-72.
26. Ory HW. Cardiovascular safety of oral contraceptives. What has changed in the last decade? Contraception 1998; 58(Suppl.):9-13S.
27. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339:285-91.
28. Arnason BG, Richman DP. Effects of estrogen, progestin and combined estrogen-progestin oral contraceptive preparations on experimental allergic encephalomyelitis. Trans Am Neurol Assoc 1969; 94:54-8.
29. Sicotte NL, Liva SM, Klutch R, Pfeiffer P, Bouvier S, Odesa S, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002; 52:421-8.
30. Poser S, Raun NE, Wikstrom J, Poser W. Pregnancy, oral contraceptives and multiple sclerosis. Acta Neurol Scand 1979; 59:108-18.
31. Hernan MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A. Oral contraceptives and the incidence of multiple sclerosis. Neurology 2000; 55:848-54.
32. Swank RL. Multiple sclerosis; a correlation of its incidence with dietary fat. Am J Med Sci 1950; 220:421-30.
33. Swank RL, Lerstad O, Strom A, Backer J. Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. N Engl J Med 1952; 246:722-8.
34. Wright HP, Thompson RH, Zilkha KJ. Platelet adhesiveness in multiple sclerosis. Lancet 1965; 2:1109-10.
35. Swank RL. Effect of high fat feedings on viscosity of the blood. Science 1954; 120:427-8.
36. Alter M, Yamoor M, Harshe M. Multiple sclerosis and nutrition. Arch Neurol 1974; 31:267-72.
37. Thompson RH. A biochemical approach to the problem of multiple sclerosis. Proc R Soc Med 1966; 59:269-76.
38. Piantadosi S, Byar DP, Green SB. The ecological fallacy. Am J Epidemiol 1988; 127:893-904.
39. Ben-Shlomo Y, Davey SG, Marmot MG. Dietary fat in the epidemiology of multiple sclerosis: Has the situation been adequately assessed? Neuroepidemiology 1992; 11:214-25.
40. Coo H, Aronson KJ. A systematic review of several potential non-genetic risk factors for multiple sclerosis. Neuroepidemiology 2004; 23:1-12.
41. Zhang SM, Hernan MA, Olek MJ, Spiegelman D, Willett WC, Ascherio A. Intakes of carotenoids, vitamin C, and vitamin E and MS risk among two large cohorts of women. Neurology 2001; 57:75-80.
42. Hewson DC, Phillips MA, Simpson KE, Drury P, Crawford MA. Food intake in multiple sclerosis. Hum Nutr Appl Nutr 1984; 38:355-67.
43. Slawta JN, Wilcox AR, McCubbin JA, Nalle DJ, Fox SD, Anderson G. Health behaviors, body composition, and coronary heart disease risk in women with multiple sclerosis. Arch Phys Med Rehabil 2003; 84:1823-30.
44. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41:1193-6.
45. Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004; 127:844-50.
46. Giubilei F, Antonini G, Di LS, Sormani MP, Pantano P, Antonini R, et al. Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurol Scand 2002; 106:109-12.
47. Kurtzke JF, Page WF. Epidemiology of multiple sclerosis in US veterans: VII. Risk factors for MS. Neurology 1997; 48:204-13.
48. Knuiman JT, West CE, Katan MB, Hautvast JG. Total cholesterol and high density lipoprotein cholesterol levels in populations differing in fat and carbohydrate intake. Arteriosclerosis 1987; 7:612-19.
49. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis. Med Decis Making 2002; 22:506-13.
50. Prosser LA, Weinstein MC. Do risk attitudes differ across domains and respondent types? Med Decis Making 2001; 21:242 (Abs).
51. Dalton CM, Chard DT, Davies GR, Miszkiel KA, Altmann DR, Fernando K, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127:1101-7.
52. Paulley JW. Psychological management of multiple sclerosis. An overview. Psychother Psychosom 1976; 27:26-40.
53. Pratt RT. An investigation of the psychiatric aspects of disseminated sclerosis. J Neurol Neurosurg Psychiatry 1951; 14:326-35.
54. Braceland FJ, Giffin ME. The mental changes associated with multiple sclerosis (an interim report). Res Publ Assoc Res Nerv Ment Dis 1950; 28:450-5.
55. Alter M, Speer J. Clinical evaluation of possible etiologic factors in multiple sclerosis. Neurology 1968; 18:109-16.
56. Cohen A. Personality aspects of multiple sclerosis. A review of the literature from 1950 through 1961. J Rehabil 1962; 28:18-20.
57. Benedict RH, Priore RL, Miller C, Munschauer F, Jacobs L. Personality disorder in multiple sclerosis correlates with cognitive impairment. J Neuropsychiatry Clin Neurosci 2001; 13:70-6.
58. Wilson H, Olson WH, Gascon GG, Brumback RA. Personality characteristics and multiple sclerosis. Psychol Rep 1982; 51:791-806.
59. Hawkes CH, Ramkumar N, Lyon J. Multiple Sclerosis in Mormons: preliminary Observations. Mult Scler 2003; 9(suppl. 1):189.
60. Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 2003; 61:1373-7.
61. Kurtzke JF, Page WF. Epidemiology of multiple sclerosis in US veterans: VII. Risk factors for MS. Neurology 1997; 48:204-13.
62. Al-Rajeh RS, Bademosi O, Ismail H, Awada A, Dawodu A, al-Freihi H, et al. A community survey of neurological disorders in Saudi Arabia: The Thugbah study. Neuroepidemiology 1993; 12:164-78.
63. Razdan S, Kaul RL, Motta A, Kaul S, Bhatt RK. Prevalence and pattern of major neurological disorders in rural Kashmir (India) in 1986. Neuroepidemiology 1994; 13:113-19.
64. Nattiv A, Puffer JC, Green GA. Lifestyles and health risks of collegiate athletes: A multi-center study. Clin J Sport Med 1997; 7:262-72.
65. Peretti-Watel P, Guagliardo V, Verger P, Pruvost J, Mignon P, Obadia Y. Sporting activity and drug use: Alcohol, cigarette and cannabis use among elite student athletes. Addiction 2003; 98:1249-56.
66. Davis TC, Arnold C, Nandy I, Bocchini JA, Gottlieb A, George RB, et al. Tobacco use among male high school athletes. J Adolesc Health 1997; 21:97-101.
67. Melnick MJ, Miller KE, Sabo DF, Farrell MP, Barnes GM. Tobacco use among high school athletes and nonatieletes: Results of the 1997 youth risk behavior survey. Adolescence 2001; 36:727-47.
68. Rainey CJ, McKeown RE, Sargent RG, Valois RF. Patterns of tobacco and alcohol use among sedentary, exercising, nonathletic, and athletic youth. J Sch Health 1996; 66:27-32.
69. Holly EA, Cress RD, Ahn DK, Aston DA, Kristiansen JJ, Felton JS. Characteristics of women by smoking status in the San Francisco Bay Area. Cancer Epidemiol Biomarkers Prev 1992; 1:491-7.
70. Valois RF, Oeltmann JE, Waller J, Hussey JR. Relationship between number of sexual intercourse partners and selected health risk behaviors among public high school adolescents. J Adolesc Health 1999; 25:328-35.
71. Ogletree RJ, Dinger MK, Vesely S. Associations between number of lifetime partners and other health behaviors. Am J Health Behav 2001; 25:537-44.
72. Bell R, Wechsler H, Johnston LD. Correlates of college student marijuana use: Results of a US National Survey. Addiction 1997; 92:571-81.
73. Guo J, Chung IJ, Hill KG, Hawkins JD, Catalano RF, Abbott RD. Developmental relationships between adolescent substance use and risky sexual behavior in young adulthood. J Adolesc Health 2002; 31:354-62.
74. Dean G, Elian M. Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 63:565-8.
75. Norman JE Jr., Kurtzke JF, Beebe GW. Epidemiology of multiple sclerosis in U.S. veterans: 2. Latitude, climate and the risk of multiple sclerosis. J Chronic Dis 1983; 36:551-9.
76. van der Mei I, Ponsonby AL, Blizzard L, Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 2001; 20:168-74.
77. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996; 93:7861-4.
78. Ponsonby AL, McMichael A, van der Mei, I. Ultraviolet radiation and autoimmune disease: Insights from epidemiological research. Toxicology 2002; 181-182:71-8.
79. Cosman F, Nieves J, Komar L, Ferrer G, Herbert J, Formica C, et al. Fracture history and bone loss in patients with MS. Neurology 1998; 51:1161-5.
80. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994; 44:1687-92
81. van der Mei I, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: Case-control study. Br Med J 2003; 327:316.
82. Goldacre MJ, Seagroatt V, Yeates D, Acheson ED. Skin cancer in people with multiple sclerosis: A record linkage study. J Epidemiol Community Health 2004; 58:142-4.
83. Freedman DM, Dosemeci M, Alavanja MC. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: A case-control study based on death certificates. Occup Environ Med 2000; 57:418-21.
84. Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willett WC, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62:60-5.
85. Dawodu A, Absood G, Patel M, Agarwal M, Ezimokhai M, Abdulrazzaq Y, et al. Biosocial factors affecting vitamin D status of women of childbearing age in the United Arab Emirates. J Biosoc Sci 1998; 30:431-7.
86. Guzel R, Kozanoglu E, Guler-Uysal F, Soyupak S, Sarpel T. Vitamin D status and bone mineral density of veiled and unveiled Turkish women. J Womens Health Gend Based Med 2001; 10:765-70.
87. al-Din AS, el-Khateeb M, Kurdi A, Mubaidin A, Wriekat A, al-Shehab A, et al. Multiple sclerosis in Arabs in Jordan. J Neurol Sci 1995; 131:144-9.
88. Wandinger K, Jabs W, Siekhaus A, Bubel S, Trillenberg P, Wagner H, et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000; 55:178-84
89. Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernan MA, Olek MJ, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: A prospective study. JAMA 2001; 286:3083-8.
90. Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, et al. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005; 293:2496-500.
91. Crawford DH, Swerdlow AJ, Higgins C, McAulay K, Harrison N, Williams H, et al. Sexual history and Epstein-Barr virus infection. J Infect Dis 2002; 186:731-6.
92. Sixbey JW, Lemon SM, Pagano JS. A second site for Epstein-Barr virus shedding: The uterine cervix. Lancet 1986; 2:1122-4.
93. Kapranos N, Petrakou E, Anastasiadou C, Kotronias D. Detection of herpes simplex virus, cytomegalovirus, and Epstein-Barr virus in the semen of men attending an infertility clinic. Fertil Steril 2003; 79(Suppl. 3):1566-70.
94. Hernan MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: A prospective study. Neurology 2004; 63:838-42.
95. Destefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003; 60:504-9.
96. Touze E, Fourrier A, Rue-Fenouche C, Ronde-Oustau V, Jeantaud I, Begaud B, et al. Hepatitis B vaccination and first central nervous system demyelinating event: A case-control study. Neuroepidemiology 2002; 21:180-6.
97. Zipp F, Wandinger KP. [Current concepts on vaccinations in multiple sclerosis]. Nervenarzt 2001; 72:802-6.
98. Ascherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Brodovicz K, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001; 344:327-32.
99. MacIntyre CR, Kelly H, Jolley D, Butzkueven H, Salmon D, Halsey N, et al. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2005; 64:1317.
100. Ferrante P, Castellani P, Barbi M, Bergamini F. The Italian Cooperative Multiple Sclerosis case-control study: Preliminary results on viral antibodies. Ital J Neurol Sci 1987; (Suppl 6):45-50.
101. Hawkes CH, Giovannoni G, Thompson EJ, Cunnington M. Raised prevalence of herpes simplex type-2 antibody in multiple sclerosis. Multiple Sclerosis 2005; 11(Suppl. 1):519.
102. Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. Br Med J 1994; 9:1325-9.